Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Bone Biologics Corp filings on SEC EDGAR ↗
Bone Biologics Corp reported a net loss of $2,157,341 for the nine months ended September 30, 2026, compared to a loss of $2,424,348 in the prior year period. The company remains in the development stage with zero revenue, focusing its expenditures on research and development for its NELL-1/DBM product candidate.
Bone Biologics Corp held its Annual Meeting of stockholders on September 28, 2026, where shareholders elected four directors and ratified Weinberg & Company, P.A. as the independent auditor. Stockholders also approved a potential reverse stock split at a ratio between 1-for-2 and 1-for-10 and authorized the potential issuance of shares underlying warrants in excess of 20% of outstanding stock to comply with Nasdaq rules.
Bone Biologics Corp received a deficiency notice from Nasdaq on September 10, 2026, because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has 180 calendar days, until March 9, 2027, to regain compliance and intends to seek shareholder approval for a reverse stock split to address the deficiency.